Back to All Posts

AMCP Nexus 2026: Perspectives on Policy, Rare Disease, and Oncology

At AMCP Nexus 2026 in San Diego, the Nexus Health Group team explored some of the issues shaping today’s market access landscape, from an evolving policy environment and growing evidence expectations in rare disease to the realities of managing access and affordability in oncology.

Across these areas, one theme was consistent: as innovative therapies and the healthcare landscape become increasingly complex, understanding the payer perspective is essential to developing effective market access strategies.

Here’s what our team found.

Policy in Focus

The policy landscape is evolving quickly, with changes at both the federal and state levels creating new considerations for pricing, contracting, coverage, and access. For manufacturers, understanding how these policies move from legislation to implementation is becoming an increasingly important part of market access planning.

One theme came through clearly: policy is becoming a major driver of market access strategy.

1. PBM reform is shifting from legislation to implementation.

The discussion is no longer whether changes are coming, but how plans, PBMs, and manufacturers adapt to new transparency and reporting requirements.

2. Medicare pricing reforms are beginning to influence access decisions beyond Medicare.

Maximum Fair Price (MFP), Most Favored Nation (MFN) models, and broader pricing reforms have implications for contracting, formulary strategy, and lifecycle management.

3. Cell and gene therapy financing remains front and center.

Stakeholders continue to explore outcome-based agreements and other models that balance patient access with affordability concerns.

4. 340B reform is becoming even more relevant for manufacturers.

Discussions focused on contract pharmacies, manufacturer restrictions, program oversight, and how potential reforms may affect channel strategy and gross-to-net economics.

5. State Prescription Drug Affordability Boards (PDABs) deserve close attention.

As states expand affordability review efforts and consider upper payment limits, manufacturers face a growing patchwork of policies that could affect access long before additional federal reforms emerge.

Bottom line: Clinical value and HEOR evidence remain foundational, but policy fluency is becoming just as important for successful market access strategy.

Rare Disease at a Turning Point

As rare disease innovation accelerates, evolving regulatory pathways, rising payer scrutiny, and growing evidence uncertainty are reshaping how manufacturers demonstrate value.

Rare disease is entering an important inflection point with the introduction of the FDA Rare Disease Framework in October 2026. The framework provides regulatory flexibility to support rare product development but raises the evidence responsibility for manufacturers. Evidence requirements should be customized to the disease and patient population, recognizing the practical limitations of small patient cohorts, alternative trial designs, and reliance on surrogate endpoints.

Greater regulatory flexibility in rare disease may accelerate development, but it also raises the bar for manufacturers to demonstrate value and resolve payer evidence uncertainty post-approval.

Coverage requirements are becoming substantially more complex in rare disease. Anticipating prior authorization requirements before launch is critical to minimizing access barriers around patient eligibility, treatment initiation, and continued coverage. Evidence planning should directly support each potential coverage criterion within the overall value proposition.

Emerging therapies will face heightened scrutiny around clinically meaningful outcomes, durability, and real-world evidence as payers demand greater certainty with the launch of high-cost, innovative therapies. The evidence bar for payer confidence often exceeds that required for FDA approval, especially when accelerated approval creates uncertainty regarding confirmatory evidence.

Patient experience data (PED) are gaining importance across regulatory and evidence-generation frameworks, though payer adoption is limited by concerns about evidence quality and rigor. While payers recognize the potential value of PED, it currently remains a low priority in their decision making. Payer impact of PED will depend on generating objective, credible, and standardized evidence early and linking it to measurable clinical, utilization, and economic outcomes.


Oncology Through a Different Lens

Looking at oncology through the payer perspective offers a different view of the challenges surrounding access, affordability, and care delivery. While much of the focus in oncology is often on the operational aspects of connecting patients with therapies, the payer lens highlights how coverage decisions, cost management, and healthcare delivery gaps can influence whether innovation ultimately reaches patients.

Key takeaways:

A proposal for a national risk pool for cell and gene therapy financing was presented, but it’s not clear that stakeholders are ready to hand over governance and administration to a federal authority.

Oncology discussions felt very transactional. With a substantial pipeline of new therapies, the focus was less on whether to cover them and more on how to manage cost through coverage policies, sequencing, and prior authorization protocols.

Budget impact matters. But depending on payer type, risk pool size, and actuarial horizon, cost per episode may have more importance than $PEPM impact.

Precision oncology isn’t just about ordering the NGS test. Practice gaps in a poorly aligned healthcare delivery system still mean that two-thirds of newly diagnosed lung cancer patients don’t gain the benefits that can be delivered by precision oncology.


Looking Across the Market Access Landscape

Taken together, these perspectives highlight just how interconnected policy, evidence, affordability, and access have become.

Policy changes are increasingly influencing strategic decisions. Innovative and high-cost therapies are creating new questions around evidence and financing. And across disease areas, manufacturers must anticipate not only what is required for regulatory approval, but what payers will need to make confident coverage decisions.

As the market evolves, understanding those perspectives early can help teams build market access strategies that better connect clinical innovation with the realities of coverage, affordability, and patient access.

About the Authors:

RYAN COX, RPh, MBA

Ryan’s insider knowledge as a former payer and more than 30 years of experience set him apart in the industry. Clients value his unique, real-world perspective on market access strategy, messaging, pull-through, and label expansions and rely on his formulary management, risk-based contracting, and deep therapeutic experience to meet access goals while optimizing utilization and reimbursement.

ILENE AUERBACH, PhD

With over 20 years of experience in healthcare communications, Ilene has successfully launched and managed ongoing lifecycle initiatives for numerous pharmacy and medical benefit products to achieve market access and commercial goals. She is known for her diverse experience across stakeholders and therapeutic areas and is recognized for partnering with clients on innovative solutions grounded in science.

JOHN HENNESSY, MBA

John Hennessy, MBA, brings extensive experience in oncology market access, coverage, health policy, and patient advocacy. A Fellow of the American Society of Clinical Oncology (FASCO) and Board-Certified Patient Advocate (BCPA), he is also an active contributor to initiatives advancing oncology care and education.